2. Academic Validation
  3. Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

  • J Med Chem. 2025 Aug 28;68(16):17457-17472. doi: 10.1021/acs.jmedchem.5c00994.
Ju Liang 1 2 3,  Yipei Gu 2,  Liuyu Hu 2,  Hui Qu 2,  Nana Li 1 2 3,  Chaoyue Xia 2 3,  Lei Feng 2,  Li Qin 2,  Li Hai 1 3,  Yaxi Yang 1 2 4 3,  Ying Leng 2,  Bing Zhou 1 2 4 3
Affiliations

Affiliations

  • 1 School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
  • 2 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • 3 University of Chinese Academy of Sciences, NO.19A Yuquan Road, Beijing 100049, P. R. China.
  • 4 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
PMID: 40762270 DOI: 10.1021/acs.jmedchem.5c00994
Abstract

With the improvement of living standards, metabolic-disorder-associated steatohepatitis (MASH) has posed a serious threat to public health. In 2024, THR-β agonist Resmetirom was approved by the FDA as the first market drug for the treatment of MASH. In this work, we discovered a new class of THR-β agonists through structure-based rational design. Compound 12 exhibited much higher agonistic activity (EC50 = 11.0 nM) and higher selectivity for THR-β over THR-α (THR-β/α = 34.1) compared to the market drug Resmetirom. More importantly, good pharmacokinetic properties of 12 was observed with an excellent liver to heart ratio of 335:1. Notably, compound 12 exhibited superior ability to improve steatosis, ballooning, inflammation and fibrosis, while Resmetirom did not show any improvement in inflammation, suggesting that 12 is a highly promising THR-β agonist and warrants extensive preclinical investigation as a potential clinical development candidate for the treatment of MASH.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z